School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.
Department of Pharmacy, Hospital Melaka, Melaka, Malaysia.
Clin Drug Investig. 2018 Jul;38(7):579-591. doi: 10.1007/s40261-018-0641-5.
Anticoagulation therapy is the fundamental approach for stroke prevention in atrial fibrillation (AF) patients. Numerous systematic reviews comparing anticoagulation strategies have been published. We aim to summarize the efficacy and safety evidence of these strategies in AF patients from previously published systematic reviews.
We searched PubMed, EMBASE and Cochrane library from inception to Feb 24th, 2017, to identify systematic reviews and meta-analyses of randomized controlled trials that assessed interventions or strategies to improve oral anticoagulant use in AF patients.
Thirty-four systematic reviews were eligible for inclusion but only 11 were included in the qualitative analyses, corresponding to 40 unique meta-analyses, as the remaining systematic reviews had overlapping primary studies. There was insufficient evidence to support the efficacy of genotype-guided dosing and pharmacist-managed anticoagulation clinics for stroke prevention in AF patients. Conversely, patient's self-management and novel oral anticoagulants (NOACs), in general were superior to warfarin for preventing stroke and reducing mortality. All interventions showed comparable risk of major bleeding with warfarin.
Findings from this overview support the superiority of NOACs and patient's self-management for preventing stroke in AF patients. However, uncertainties remain on the benefits of genotype-guided dosing and pharmacist-managed anticoagulation clinics due to poor quality evidence, and future research is warranted.
抗凝治疗是预防心房颤动(AF)患者中风的基本方法。已经发表了许多比较抗凝策略的系统评价。我们旨在总结先前发表的系统评价中这些策略在 AF 患者中的疗效和安全性证据。
我们从 2017 年 2 月 24 日之前检索了 PubMed、EMBASE 和 Cochrane 图书馆,以确定评估改善 AF 患者口服抗凝剂使用的干预措施或策略的系统评价和荟萃分析。
有 34 项系统评价符合纳入标准,但只有 11 项被纳入定性分析,对应 40 项独特的荟萃分析,因为其余的系统评价有重叠的主要研究。没有足够的证据支持基因型指导剂量和药剂师管理的抗凝诊所对 AF 患者预防中风的疗效。相反,患者的自我管理和新型口服抗凝剂(NOACs)总体上优于华法林预防中风和降低死亡率。所有干预措施与华法林相比,大出血的风险相似。
本综述的结果支持 NOACs 和患者自我管理在预防 AF 患者中风方面的优越性。然而,由于证据质量差,基因型指导剂量和药剂师管理的抗凝诊所的益处仍存在不确定性,需要进一步研究。